Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Phase 3 Recruiting 300 enrolled Valenta Pharm JSC

RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of the study is to evaluate the efficacy, safety, and tolerability of 4-MUST, 128 mg tablets compared to placebo in patients with chronic cholecystitis and biliary dyskinesia.

Timeline

Start: 2025-12-12
Primary completion: 2027-12-31
Completion: 2027-12-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	4-MUST	Unknown	384 mg	Oral

Efficacy, Safety, and Tolerability of 4-MUST, 128 mg Tablets in Chronic Cholecystitis and Biliary Dyskinesia

Summary

Timeline

Drugs

Indications